About this role
Who is USP
The U.S. Pharmacopeial Convention (USP) is an independent scientific organization that collaborates with the world's top experts in health and science to develop quality standards for medicines, dietary supplements, and food ingredients. USP's fundamental belief that Equity = Excellence manifests in our core value of Passion for Quality through our more than 1,100 talented professionals across five global locations to deliver the mission to strengthen the supply of safe, quality medicines and supplements worldwide.
Who are our Expert Volunteers?
A hallmark of USP's standards is that they are determined by independent scientific experts. USP Expert Volunteers are selected based on their individual expertise and experience and use their best personal, professional, and scientific judgment to work collaboratively on setting standards. USP Expert Volunteers must agree to disclose conflicts of interest and to uphold standards of conduct that preserve the integrity of the standard setting process.
Focus Area: Dosage Forms; Performance Testing; Medical Devices; Nanotechnology; Ophthalmic Preparations; Particulate Matter; Capsules; Injections and Implants; Topical and Mucosal Products; Continuous Manufacturing; Semisolid Dosage Forms; Veterinary Solubility; Verification Testing; Filters and Membranes
2025-2030 KEY ISSUES:
• Pharmaceutical Dosage Forms (): Enhancing practices, guidelines, and standards for pharmaceutical dosage forms.
• Dermal Dosage Forms: Improving design, development, testing, and regulatory compliance of dermal dosage forms.
• Inhalation Dosage Forms: Enhancing practices for inhalation dosage forms, including design, development, testing, and regulatory compliance.
• Oral Dosage Forms: Advancing practices related to oral dosage forms, including design, development, testing, and regulatory compliance.;
• Performance Testing: Improving practices for performance testing of pharmaceutical dosage forms, including dissolution, disintegration, and drug release.
• Data Analysis: Enhancing data analysis practices in pharmaceutical research, development, and manufacturing.
• Medical (Drug) Devices: Improving practices for the design, development, testing, and regulatory compliance of medical devices used to deliver pharmaceutical products.
• Nanotechnology: Advancing the application of nanotechnology in pharmaceutical research, development, and manufacturing.; Ophthalmic Preparations (): Enhancing standards and practices for the formulation, testing, and regulatory compliance of ophthalmic preparations.
• Particulate Matter in Injections (): Improving standards and practices for controlling, detecting, and quantifying particulate matter in injectable pharmaceutical products.
• Capsules: Enhancing practices for the design, development, testing, and regulatory compliance of capsule dosage forms.
• Injections and Implanted Drug Products: Improving practices for injectable and implanted drug products, including design, development, testing, and regulatory compliance.
• Topical and Transdermal Drug Products: Enhancing practices for topical and transdermal drug products, including design, development, testing, and regulatory compliance.
• Mucosal Drug Products: Improving practices for mucosal drug products, including design, development, testing, and regulatory compliance.;
• Continuous Manufacturing: Enhancing practices for the implementation and optimization of continuous manufacturing in pharmaceutical production.
• Nanomaterials: Advancing the use, characterization, and regulatory compliance of nanomaterials in pharmaceutical research, development, and manufacturing.; - Performance Testing for Semisolid Dosage Forms: Improving practices for testing and assessing semisolid dosage forms.
• Solubility Criteria for Veterinary Drugs: Establishing solubility criteria specifically for veterinary drugs.
• Performance Verification Testing: Enhancing practices for performance verification testing in pharmaceutical manufacturing and quality control.
• Resuspendability (): Improving practices for the resuspendability of pharmaceutical suspensions.; - Visual Inspection of Parenterals: Enhancing practices for the visual inspection of parenteral pharmaceutical products.
• Particulate Matter: Silicone Oil: Improving practices for detecting, quantifying, and controlling silicone oil as particulate matter in pharmaceutical products, particularly in parenteral formulations.
• Filters and Membranes: Enhancing practices for the selection, testing, and regulatory compliance of filters and membranes used in pharmaceutical manufacturing.
Required Expertise: Formulation development and Dosage Forms development
•
How will YOU create impact here at USP?
In this role as a USP Volunteer, you contribute to USP's public health mission of increasing equitable access to high-quality, safe medicine and improving global health through public standards and related programs.